Janssen Pharmaceutica Nv
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1953-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
16
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
News
Nanobiotix's JNJ-1900 Shows Promising Results in Anti-PD-1 Resistant Melanoma Patients
Nanobiotix announced Phase 1 results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in heavily pre-treated primary cutaneous melanoma patients resistant to anti-PD-1 therapy.
Dr. Reddy's Laboratories Acquires Johnson & Johnson's STUGERON Brand for $50.5 Million to Expand CNS Portfolio
Dr. Reddy's Laboratories has acquired the STUGERON brand from Johnson & Johnson for $50.5 million, expanding its central nervous system therapeutic portfolio across 18 markets in Asia-Pacific and EMEA regions.
Nanobiotix Secures EU Regulatory Harmonization and New Patent for Cancer Radioenhancer JNJ-1900
European health authorities have reclassified JNJ-1900 (NBTXR3) from a medical device to a medicinal product, harmonizing its regulatory status with the US and other major markets.
Contineum Therapeutics Reports Positive Phase 1b PET Trial Results for PIPE-791 in Multiple Sclerosis and Pulmonary Fibrosis
Contineum Therapeutics announced positive topline data from its Phase 1b PET trial of PIPE-791, an LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.
Contineum Therapeutics On Track for Key Clinical Milestones with PIPE-791 and PIPE-307 Programs
Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.
Nanobiotix's Radioenhancer JNJ-1900 Enters Phase 2 Trial for Unresectable NSCLC
Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer.